This finding is highly consistent with our conclusion that “the combined detection of CA50, CA242, and SAA optimizes the assessment of pancreatic cancer prognosis.” Together, these findings reinforce the applicability and superiority of using combined biomarkers over single indicators in the diagnosis and treatment of PC. This evidence concerns the gene SAA1 and familial pancreatic carcinoma.